Treatment development for systemic Tetrahymena sp. infection in guppies, Poecilia reticulata Peters.

Antibacterial and antiparasitic agents and a cysteine protease inhibitor (E-64) were tested against Tetrahymena infection, a serious problem in guppy production worldwide. Chemicals were tested in vitro by a colorimetric assay for Tetrahymena survival. The most effective were niclosamide, albendazole and chloroquine, with 23%, 35% and 60% survival, respectively, following 2-h exposure to 100 ppm. Longer incubation periods resulted in greater reductions in survival. Niclosamide was further studied in vivo at different dosages, administered orally to Tetrahymena-infected guppies. Mortality rates were significantly lower in all treatment groups; in trial I, 30% and 33% mortality in 5 and 40 mg kg(-1) niclosamide-fed fish vs. 59% mortality in controls; in trial II, 35%, 13% and 10% in 50, 100 and 200 mg kg(-1) niclosamide-fed fish vs. 64% in controls. The effect of the cysteine protease inhibitor E64 was tested in tissue culture, by measuring histolytic activity of the parasite (Tet-NI) on a guppy-fin cell line, based on cell depletion. Tet-NI feeding activity was significantly reduced following pretreatment with E-64 relative to non-treated Tet-NI. E-64-pretreated Tet-NI was injected i.p. into guppies: recorded mortality rates were significantly lower (35%) than that in non-treated Tet-NI (60%), suggesting inhibition of the parasite's cysteine protease as a possible therapeutic approach.

Cysteine proteases and acid phosphatases contribute to Tetrahymena spp. pathogenicity in guppies, Poecilia reticulata.

Systemic tetrahymenosis caused by the protozoan parasite Tetrahymena spp. is a serious problem in guppy (Poecilia reticulata) farms worldwide. There is no therapeutic solution for the systemic form of this disease. Guppies severely infected with Tetrahymena spp. were imported by a commercial ornamental fish farm and brought to our laboratory. Tetrahymena sp. (Tet-NI) was isolated and in vitro cultured. Isolates maintained in culture for different time periods (as reflected by different numbers of passages in culture) were analyzed-Tet-NI 1, 4, 5 and 6, with Tet-NI 1 being cultured for the longest period (about 15 months, 54 passages) and Tet-NI 6 for the shortest (2.5 months, 10 passages). Controlled internal infection was successfully achieved by IP injection with most isolates, except for Tet-NI 1 which produced no infection. The isolate Tet-NI 6 induced the highest infection rates in internal organs (80% vs. 50% and 64% for Tet-NI 4 and 5, respectively) and mortality rates (67% vs. 20% and 27% for Tet-NI 4 and 5, respectively, and 6.7% for Tet-NI 1). The correlation between pathogenicity and Tetrahymena enzymatic activity was studied. Electrophoretic analyses revealed at least two bands of gelanolytic activity in Tet-NI 4 and 5, three bands in Tet-NI 6, and no activity in Tet-NI 1. Total inhibition of gelanolytic activity was observed after pretreatment of Tet-NI 6 with E-64, a highly selective cysteine protease inhibitor. Using hemoglobin as a substrate, Tet-NI 6 had two bands of proteolytic activity and no bands were observed in Tet-NI 1. A correlation was observed between pathogenicity and acid phosphatase activities (analyzed by commercial fluorescence kit) for Tet-NI 1 and Tet-NI 6.

Protective immunization against Tetrahymena sp. infection in guppies (Poecilia reticulata).

Systemic tetrahymenosis constitutes a serious problem in guppy (Poecilia reticulata) production worldwide and no therapeutic solution is available for this disease. Three immunization trials were conducted, testing the effectiveness of different Tetrahymena preparations applied by intraperitoneal injection (IP) with or without Freund's complete adjuvant (FCA) and with or without booster dose. In trial 1, immunization with the pathogenic Tet-NI 6 lysate and live attenuated Tet-NI 1 did not provide significant protection from infection, although infection rates were significantly lower in the Tet-NI 6-immunized group than in controls. In trial 2, mortality in Tet-NI 6 + FCA-immunized fish was 10%, significantly lower than in all other treatment groups, including Tet-NI 6 lysate, live attenuated Tet-NI 1 and controls (77, 67 and 73%, respectively). In trial 3, the lowest mortality rates were obtained in the Tet-NI 6 + FCA + booster-immunized group (15%). These levels were lower but not significantly different from the non-boostered Tet-NI 6-immunized group (28%) and the groups immunized with Tet-NI 1, with and without booster (32 and 34%, respectively). Mortality in these four groups was significantly lower than in controls, including adjuvant- and PBS-injected groups (72 and 81%, respectively). Body homogenates of immunized fish immobilized Tetrahymena in-vitro, as compared to no or very little immobilization in controls. Lysozyme levels in the Tet-NI 6 + FCA + booster group were significantly higher than in all other treatments in trial 2 and controls in trial 3. There was no significant difference in anti-protease activity among the differently immunized fish. We conclude that immunization with Tetrahymena lysates in FCA confers a high degree of protection from infection, suggesting this preparation as a basis for vaccine development.